Philips CMO Carla Peron Joins MDIC Board to Boost Regulatory Partnerships
Royal Philips CMO Carla Goulart Peron was appointed to the Medical Device Innovation Consortium board, enhancing the company's influence on FDA regulatory science. MDIC’s public–private partnership develops frameworks to streamline device approval and coverage decisions, potentially accelerating Philips’ market access for new medical technologies.
1. Board Appointment
Carla Goulart Peron, MD, Chief Medical Officer at Royal Philips, has been appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC), strengthening Philips’ strategic involvement in regulatory collaboration.
2. Role at MDIC
In her new board role, Dr. Peron will leverage her clinical and innovation expertise to guide MDIC’s development of research toolkits and actionable frameworks that help medical device manufacturers navigate regulatory approval processes and coverage decisions.
3. MDIC Vision and Activities
MDIC, a public–private partnership since 2012, unites FDA, government agencies, manufacturers, patients and clinicians to address scientific and technical challenges, streamline quality standards and accelerate patient access to safe, effective medical devices.
4. Strategic Benefits for Philips
By securing a seat on MDIC’s board, Philips aims to align its product development and medical strategy with evolving regulatory science, potentially reducing time to market and enhancing adoption of its imaging, monitoring and therapy solutions.